Vivo Capital

Vivo Capital, LLC is a private equity and venture capital firm founded in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. The firm specializes in healthcare investments across various stages, including early stage, growth capital, and public equity. With approximately $5.8 billion in assets under management, Vivo has invested in over 290 public and private companies globally. Its focus lies primarily in biopharmaceuticals, specialty pharmaceuticals, medical devices, and healthcare services, targeting companies in the U.S. and East Asia, particularly China. Vivo aims to invest between $2 million and $40 million, typically favoring minority equity stakes. The firm's multi-disciplinary team includes professionals with backgrounds in medicine, science, and entrepreneurship, allowing it to effectively navigate the complexities of the healthcare sector.

Gaurav Aggarwal

Managing Director

Chen Bian

Associate

Wei Bian

Analyst

Cyber Cao

Managing Director

Mike Chang

Managing Partner

Albert Chang

Executive Director

Kevin Dai

Managing Director

Nathan Dau

Managing Director

Hao Dong

Managing Director

Shan Fu

Managing Partner

Andrew Huang

Principal

Shen Jo

Venture Partner

Frank Kung

Managing Partner

Yixuan Li

Executive Director

David Liu

Managing Director

Sean Lo

Principal

Hongbo Lu

Managing Partner

Zhongyi Lu

Principal

John Massad

Managing Director

Mitchell Mutz

Entrepreneur Partner

Fabianne Nordenson

Principal

Daniel Qin

Associate

Sue Shao

Principal

Joseph Siletto

Managing Director

Timothy Stubbs

Principal

Priscilla Sugianto

Principal

Jason Wang

Principal

Scott Whitcup

Venture Partner

Daisy Xu

Managing Director

Gisele Zhang Ph.D

Principal

Chloe Zhang

Principal

Lingfei Zhao

Analyst - Investment and Portfolio Management

Xiaoyang li

Associate

Xiong Zhang Ph.D

Principal, Venture Capital

Frank Kung Ph.D

Co-Founder and Managing Partner

Past deals in Nepal

Sinovac

Post in 2018
Sinovac Biotech Ltd. is a biopharmaceutical company based in Beijing, China, specializing in the research, development, manufacture, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and enterovirus 71, among others. Key marketed products include Healive, a hepatitis A vaccine, Bilive, a combined hepatitis A and B vaccine, and Panflu.1, which was the first H1N1 vaccine approved globally. Sinovac also plays a significant role in government stockpiling programs for vaccines in China. The company is actively developing new vaccines, including those for pneumococcal disease and rubella, with various clinical trials underway. Sinovac collaborates with notable institutions such as GlaxoSmithKline and Tianjin CanSino Biotechnology to enhance its vaccine development efforts. Established in 1999, Sinovac primarily sells its products in China while also exporting selected vaccines to countries like Mongolia, Nepal, and the Philippines.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.